Powered by Mass Cytometry
Publications from a variety of academic and industry groups, including work co-authored by Teiko scientists, demonstrate the critical role that peripheral blood plays in the treatment of cancer
Comprehensive immune monitoring of clinical trials to advance human immunotherapy
Hartmann et al. describes the development and utilization of a comprehensive and easily customizable 33-marker mass cytometry panel optimized for immune monitoring of clinical trials.
Systemic immunity Is required for effective cancer immunotherapy
In this seminal Cell 2017 publication, Spitzer, Carmi & Reticker-Flynn et al. show that effective immunotherapy treatment requires peripheral immune cell engagement in both breast and colon cancer mouse models.
Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes
Rahim, Okholm, & Jones et al. show that immune checkpoint blockade activates CD8 T cell differentiation and proliferation in the lymph node, not within the tumor microenvironment, and these cells can be detected in transit via blood profiling.
Single-cell analysis of Crohn’s disease lesions identifies a pathogenic cellular module associated with resistance to anti-TNF therapy
Martin et al. use single cell sequencing validated by mass cytometry to identify a 4-subset signature for predictive scoring of response to anti-TNF treatment among patients with ileal Crohn’s disease.
Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy
Prokopi et al. use mass cytometry to track dendritic cell and T cell subsets in both the tumor and tumor-draining lymph nodes and identify distinct patterns of migration and recruitment throughout melanoma progression and treatment.
Mass cytometry reveals classical monocytes, NK cells, and ICOS+ CD4+ T cells associated with pembrolizumab efficacy in patients with lung cancer
Rochigneux et al. identify new blood-based candidate immune cell biomarkers associated with successful clinical outcomes to anti-PD-1 therapy for a subset of NSCLC patients in the KEYNOTE-001 trial.
Post-infusion CAR Treg cells identify patients resistant to CD19-CAR therapy
Using mass cytometry, Good et al. profiled post-infusion CAR T cells in patients with large B cell lymphoma and identified a novel population of CAR Tregs associated with disease progression and decreased neurotoxicity.
A single-cell atlas of the tumor and immune ecosystem of human breast cancer
Using mass cytometry, Wagner et al. profile 73 proteins across nearly 200 samples of breast tumor and adjacent non-tumor tissue to identify novel features of tumor composition linked to poor prognosis.
Identifying predictors of survival in patients with leukemia using single-cell mass cytometry and machine learning
Kleftogiannis et al. developed a machine learning framework using mass cytometry data from 45 leukemia patients and identified predictive biomarkers of survival
Deep analysis of the peripheral immune system in IBD reveals new insight in disease subtyping and response to monotherapy or combination therapy
Kosoy et al. profiled immune composition of nearly 1200 patients with IBD and over 300 controls using mass cytometry and identified key immune subsets target by combination therapy.
Distinct injury responsive regulatory T cells identified by multi-dimensional phenotyping
In Guo et al., the team used mass cytometry in combination with RNA and TCR sequencing to validate two unique clusters of regulatory T cells (Treg) that respond differently to injury.
Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma
The team Simonds, Lu, & Badillo et al. used mass cytometry determine why glioblastoma, the most common malignant brain tumor, is also the most resistant to immunotherapy.